US2013065815A1PendingUtilityA1

Fn 14/TRAIL Fusion Proteins

50
Individually held — no corporate assignee on recordPriority: Jun 30, 2008Filed: Aug 15, 2012Published: Mar 14, 2013
Est. expiryJun 30, 2028(~1.9 yrs left)· nominal 20-yr term from priority
Inventors:Mark L. TykocinskiMarjaneh Razmara
A61P 37/06A61P 35/00A61P 43/00A61P 35/02A61P 37/02A61P 25/00C07K 14/70575A61P 11/00A61P 1/04A61P 15/00A61P 1/16C07K 2319/00A61P 17/00C07K 14/705
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer.

Claims

exact text as granted — not AI-modified
1 - 23 . (canceled) 
     
     
         24 . A method of treating or ameliorating autoimmune disease in a patient by administering to said patient an effective amount of a pharmaceutical composition comprising a pharmaceutical acceptable carrier and a genetic sequence encoding a fusion protein, wherein the fusion protein comprises a first domain and a second domain, wherein the first domain is a polypeptide that binds to TWEAK and the second domain is a polypeptide that binds to a TRAIL receptor, wherein the first domain main is at least a portion of the extracellular domain of Fn14 protein and the second domain is at least a portion of the extracellular domain of a TRAIL protein. 
     
     
         25 . The method of  claim 24 , wherein the autoimmune disease is multiple sclerosis. 
     
     
         26 . The method of  claim 24 , wherein the fusion protein is SEQ ID NO: 1 or SEQ ID NO: 2. 
     
     
         27 . The method of  claim 24 , wherein the fusion protein consists of a first domain and a second domain, wherein the first domain is at least a TWEAK-binding portion of the extracellular domain of Fn14 protein and the second domain is at least a TRAIL receptor-binding portion of the extracellular domain of TRAIL protein. 
     
     
         28 . The method of  claim 24 , wherein the first domain is human Fn14 and the second domain is human TRAIL. 
     
     
         29 . The method of  claim 24 , wherein the administration is parenteral. 
     
     
         30 . The method of  claim 24 , wherein the patient has an alloimmune disease. 
     
     
         31 . A method of treating or ameliorating an autoimmune disease in a patient having an autoimmune disease comprising administering an effective amount of a pharmaceutical composition comprising a fusion protein and a pharmaceutical acceptable carrier, wherein the fusion protein comprises a first domain and a second domain, wherein the first domain is a polypeptide that binds to TWEAK and the second domain is a polypeptide that binds to a TRAIL receptor, wherein the first domain is at least a portion of the extracellular domain of Fn14 protein and the second domain is at least a portion of the extracellular domain of a TRAIL protein. 
     
     
         32 . The method of  claim 31 , wherein the autoimmune disease is multiple sclerosis. 
     
     
         33 . The method of  claim 31 , wherein the fusion protein is SEQ ID NO: 1 or SEQ ID NO: 2. 
     
     
         34 . The method of  claim 31 , wherein the fusion protein consists of a first domain and a second domain, wherein the first domain is at least a TWEAK-binding portion of the extracellular domain of Fn14 protein and the second domain is at least a TRAIL receptor-binding portion of the extracellular domain of TRAIL protein. 
     
     
         35 . The method of  claim 31 , wherein the first domain is human Fn14 and the second domain is human TRAIL. 
     
     
         36 . The method of  claim 31 , wherein the administration is parenteral. 
     
     
         37 . The method of  claim 31 , wherein the patient has an alloimmune disease.

Join the waitlist — get patent alerts

Track US2013065815A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.